Wave Life Sciences shares tumbled after the company published interim Phase 1 findings from its INLIGHT study assessing WVE-007 as a treatment for obesity. The market reaction followed data showing divergent signals between dose cohorts in the small study.
Key trial results
The company reported that the 240 mg dose of WVE-007 produced a placebo-adjusted visceral fat loss of 14.3% at six months, up from 7.8% at the three-month readout. By contrast, a single 400 mg dose did not demonstrate a dose response in the reported data: patients with elevated baseline visceral fat levels in the 400 mg cohort experienced a 7.8% visceral fat reduction at three months.
Wave Life Sciences said the divergence may reflect differences in the trial population rather than an inherent ceiling on efficacy. Management pointed to the relatively lower body mass index - BMI - of patients enrolled in INLIGHT versus participants in other obesity studies as a likely factor limiting observable fat reductions, and suggested that greater reductions could occur in patients with higher baseline BMI.
Next steps from the company
The firm plans to start a Phase 2a study in the second quarter of 2026. That follow-up will specifically enroll patients with higher BMI in the 35-50 kg/m2 range and will include individuals with comorbidities, reflecting the company’s view that the INLIGHT cohort’s lower BMI may have constrained the signal.
Analyst reactions and valuation moves
Analysts reacted by revising their assumptions and valuations. Raymond James noted the update raised questions about WVE-007’s potential as a monotherapy but kept an Outperform rating while lowering its price target to $12. The Raymond James team added: "We continue to think that combo and maintenance options represent sizable potential commercial opportunities."
Bank of America cut its price target to $21 from $38, reducing its peak penetration estimate for monotherapy from 0.82% to 0.5% and lowering the probability of success from 30% to 20%. BofA analysts wrote: "We think more is needed to convince investors of the potential for WVE-007, especially as monotherapy, to drive weight loss closer to the 5% weight loss threshold."
Jefferies highlighted that the data validated the INHBE fat-targeting mechanism by showing durable fat loss while preserving muscle. However, Jefferies also acknowledged that the Phase 1 population’s lower BMI relative to competitor trials likely limited the observable treatment effect and said this could create near-term pressure on the stock.
Context and implications
The interim INLIGHT readout offers mixed signals: the 240 mg cohort’s sustained visceral fat reduction at six months provides a signal of activity, while the absence of a clear dose response at the single 400 mg dose raises questions about dose optimization and the drug’s standalone efficacy profile. The company’s plan to enroll a higher-BMI, comorbid population in Phase 2a aims to address the enrollment composition issue cited as potentially dampening the Phase 1 effect size.
Investors and market participants will be watching the Phase 2a enrollment criteria and subsequent readouts for evidence that efficacy scales in a heavier, more comorbid population, as well as any data on combination or maintenance regimens that analysts identified as alternative commercial pathways.